These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 26174895)
1. Complementary use of passive surveillance and Mini-Sentinel to better characterize hemolysis after immune globulin. Winiecki S; Baer B; Chege W; Jankosky C; Mintz P; Baker M; Woodworth T; Nguyen M Transfusion; 2015 Jul; 55 Suppl 2():S28-35. PubMed ID: 26174895 [TBL] [Abstract][Full Text] [Related]
2. Intravenous immune globulin-related hemolysis: comparing two different methods for case assessment. Taylor E; Vu D; Legare C; Keene D Transfusion; 2015 Jul; 55 Suppl 2():S23-7. PubMed ID: 26174894 [TBL] [Abstract][Full Text] [Related]
3. Hemolytic events after the administration of lyophilized versus liquid immune globulin: an analysis of a single manufacturer's safety database. Berg R; Jacob D; Fuellenhals E Transfusion; 2015 Aug; 55(8):1847-54. PubMed ID: 25867204 [TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease. Luban NL; Wong EC; Henrich Lobo R; Pary P; Duke S Transfusion; 2015 Jul; 55 Suppl 2():S90-4. PubMed ID: 26174904 [TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura. Bussel JB; Hanna K; Am J Hematol; 2007 Mar; 82(3):192-8. PubMed ID: 17109385 [TBL] [Abstract][Full Text] [Related]
6. Acute renal failure after intravenous anti-D immune globulin in an adult with immune thrombocytopenic purpura. Chun NS; Savani B; Seder RH; Taplin ME Am J Hematol; 2003 Dec; 74(4):276-9. PubMed ID: 14635210 [TBL] [Abstract][Full Text] [Related]
7. Investigation of whether the acute hemolysis associated with Rh(o)(D) immune globulin intravenous (human) administration for treatment of immune thrombocytopenic purpura is consistent with the acute hemolytic transfusion reaction model. Gaines AR; Lee-Stroka H; Byrne K; Scott DE; Uhl L; Lazarus E; Stroncek DF Transfusion; 2009 Jun; 49(6):1050-8. PubMed ID: 19220820 [TBL] [Abstract][Full Text] [Related]
8. Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports. Padmore R Transfusion; 2015 Jul; 55 Suppl 2():S59-64. PubMed ID: 26174898 [TBL] [Abstract][Full Text] [Related]
9. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Gaines AR Blood; 2000 Apr; 95(8):2523-9. PubMed ID: 10753830 [TBL] [Abstract][Full Text] [Related]
10. The product: All intravenous immunoglobulins are not equivalent. Siegel J Pharmacotherapy; 2005 Nov; 25(11 Pt 2):78S-84S. PubMed ID: 16229678 [TBL] [Abstract][Full Text] [Related]
11. IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. Bussel JB; Eldor A; Kelton JG; Varon D; Brenner B; Gillis S; Angiolillo A; Kulkarni R; Abshire TC; Kelleher J; Thromb Haemost; 2004 Apr; 91(4):771-8. PubMed ID: 15045139 [TBL] [Abstract][Full Text] [Related]
12. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura. El Alfy MS; Mokhtar GM; El-Laboudy MA; Khalifa AS Acta Haematol; 2006; 115(1-2):46-52. PubMed ID: 16424649 [TBL] [Abstract][Full Text] [Related]